"approved"@en . . . . . . . . . . "Humans and other mammals"@en . . . "5-aza-2'-deoxycytidine"@en . . "Decitabine"@en . . "2353-33-5"@en . " "@en . "Decitabine is indicated for treatment of patients with myelodysplastic syndrome (MDS). It is a chemical analogue of cytidine, a nucleoside present in DNA and RNA. Cells in the presence of Decitabine incorporate it into DNA during replication and RNA during transcription. The incorporation of Decitabine into DNA or RNA inhibits methyltransferase thereby causing demethylation in that sequence. This adversely affects the way that cell regulatory proteins are able to bind to the DNA/RNA substrate."@en . "5-Azadeoxycytidine"@en . . . . . "Decitabine is believed to exert its antineoplastic effects following its conversion to decitabine triphosphate, where the drug directly incorporates into DNA and inhibits DNA methyltransferase, the enzyme that is responsible for methylating newly synthesized DNA in mammalian cells. This results in hypomethylation of DNA and cellular differentiation or apoptosis. Decitabine inhibits DNA methylation in vitro, which is achieved at concentrations that do not cause major suppression of DNA synthesis. Decitabine-induced hypomethylation in neoplastic cells may restore normal function to genes that are critical for the control of cellular differentiation and proliferation. In rapidly dividing cells, the cytotoxicity of decitabine may also be attributed to the formation of covalent adducts between DNA methyltransferase and decitabine that has been incorporated into DNA. Non-proliferating cells are relatively insensitive to decitabine. Decitabine is cell cycle specific and acts peripherally in the S phase of the cell cycle. It does not inhibit the progression of cells from the G1 to S phase."@en . . "There is no known antidote for overdosage with decitabine. Higher doses are associated with increased myelosuppression including prolonged neutropenia and thrombocytopenia. "@en . . . . . . "Julian Paul Henschke, Xiaoheng Zhang, Jianbo Yu, Kun Hu, Lijun Mei, \"Synthesis of Decitabine.\" U.S. Patent US20100087637, issued April 08, 2010."@en . . . . . . . "Azadc"@en . "investigational"@en . . "Plasma protein binding of decitabine is negligible (<1%). "@en . . . . . . "Dezocitidine"@en . "* 125 L/h/m2 [Patients receiving 15 mg/m2 3-hr infusion every 8 hours for 3 days] * 210 L/h/m2 [20 mg/m2 1-hr infusion daily for 5 days]"@en . . . . . . "For treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups (scores \u22650.5)."@en . . . "Decitabine"@en . . "The terminal phase elimination half-life is 0.51 ± 0.31 hours."@en . . . "4-amino-1-(2-Deoxy-beta-D-erythro-pentofuranosyl)-S-triazin-2(1H)-one"@en . . . "# Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, Lee C, Barrett S, Reade S, Jadayel D, Tang A, Bellenger K, Mackay L, Setanoians A, Schatzlein A, Twelves C, Kaye SB, Brown R: Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol. 2007 Oct 10;25(29):4603-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17925555 # Wijermans PW, Ruter B, Baer MR, Slack JL, Hussain SI, Lubbert M: Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res. 2007 Sep 17;. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17881052 # Daskalakis M, Blagitko-Dorfs N, Hackanson B: Decitabine. Recent Results Cancer Res. 2010;184:131-57. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20072836 # Saba HI, Wijermans PW: Decitabine in myelodysplastic syndromes. Semin Hematol. 2005 Jul;42(3 Suppl 2):S23-31. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16015501 # Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H: Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer. 2008 Jun;112(11):2341-51. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18398832 # Stresemann C, Lyko F: Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer. 2008 Jul 1;123(1):8-13. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18425818 # Oki Y, Aoki E, Issa JP: Decitabine--bedside to bench. Crit Rev Oncol Hematol. 2007 Feb;61(2):140-52. Epub 2006 Oct 4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17023173"@en . . .